Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Recruiting · NCT05726370 · Registry updated 2026-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-06-23 | NCT05726370 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Merck Sharp & Dohme LLC | 650 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |